Sentien Announces First Subject Dosed in Phase 1/2 Trial of Ex Vivo MSC Therapy for the Treatment of Severe COVID-19
Filter: PRESS RELEASES IN THE NEWS EVENTS
Sentien Biotechnologies Announces First Subject Dosed in Phase 1/2 Trial of Ex Vivo MSC Therapy for the Treatment of Severe COVID-19
November 23, 2020 Press Release